Back to News
Market Impact: 0.4
Aquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Aquestive Therapeutics resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film intended to treat Type I allergic reactions including anaphylaxis. The resubmission is supported by positive topline data, advancing the product toward a potential FDA decision and creating a meaningful regulatory catalyst for AQST.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
AQST0.55
More News
- UN mission finds evidence of U.S. war crimes in Iran; Washington rejects report
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car
- Warsh spooks investors, OpenAI's 'concerning' incidents, Boeing's production problems and more in Morning Squawk
- AI coding agents' 0-click RCE flaw could hand attackers keys to the kingdom